Sign in
Active, not recruitingNo phase

Pilot Study of The EPIC Trial

Key facts

Who runs it
Ottawa Hospital Research Institute
Where
Canada5 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
20 people, planned
Started
Aug 2015
Ended
Dec 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Endoscopic Polypectomy Performed in Clinic
  • Functional Endoscopic Sinus Surgery (FESS)
Record updated
30 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Age 18 years or older
  • Diagnosis of chronic rhinosinusitis with polyps requiring surgical treatment after having been treated with medical therapy as designated by the Canadian clinical practice guidelines for acute and chronic sinusitis. 21
  • Bilateral nasal polyps present of Grade ≥ 2 on each side as determined by the Lildholdt scale score measured by nasal endoscopy (Appendix 2) at the screening visit
  • Must have nasal blockage score greater than or equal to 4 on the sinonasal outcome test SNOT-22 (Appendix 3) at the screening visit
  • Must have an American Society of Anesthesiologists physical status (ASA PS) 3 classification or less. ASA PS 3: Patients with severe systemic disease: Some functional limitation; has a controlled disease of more than one body system or one major system; no immediate danger of death. ASA PS 2: Patients with mild systemic disease. No functional limitations; has a well-controlled disease of one body system. ASA PS 1: Normal healthy patient. No organic, physiologic, or psychiatric disturbance; excludes the very young and very old
  • Participants with comorbid asthma or chronic obstructive pulmonary disease (COPD) must have stable disease with no exacerbations (no emergency room visits, hospitalisations, or oral or parental steroid use for these lower respiratory conditions) within 3 months before the screening visit
  • Must be capable, in the opinion of the investigator, of providing informed consent to participate in the study. Participants must sign an informed consent document indicating that they understand the purpose of and procedures of the study and are willing to participate in the study

Who cannot take part

  • Any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator, could confound the results of the study or could interfere with the participant's participation or compliance with the study
  • Any participant who is unfit to undergo surgery under general anesthesia
  • History of any surgical procedure that prevents the ability to accurately grade the nasal polyps
  • Diagnosis of allergic fungal sinusitis
  • Contraindication to the use of oral corticosteroids (e.g. uncontrolled diabetes, congestive heart failure, uncontrolled hypertension, known renal insufficiency, known peptic ulcer disease, known glaucoma, pregnancy)
  • History of either Churg-Strauss syndrome, primary ciliary dyskinesia, or vasculitis (e.g. granulomatosis with polyangiitis(GPA))
  • Allergy, hypersensitivity, or contraindication to the use of local or topical lidocaine anesthetics, nasal topical 1:1000 adrenaline, nasal decongestants, nasal steroid spray
  • A recent (within 1 year of the screening visit) clinically significant history of drug or alcohol abuse, or dependence that, in the opinion of the investigator could interfere with the participant's participation or compliance with the study
  • Any medical condition that in the opinion of the investigator would interfere with the treatment
  • Diagnosis or Aspirin Exacerbated Respiratory Disease (AERD)
  • Women who are pregnant or breast feeding
  • Patients with hyperplastic polyps or polyps large enough that they result in external nasal deformity
  • Facial pain/pressure score higher than 2 on the sinonasal outcome test SNOT-22 at the screening visit
  • Participants who will not be able to complete the follow-up appointments/evaluations
  • Have significant oral structural abnormalities, e.g. unrepaired cleft palate
  • Septal deviation requiring correction in order to perform either EPIC or FESS procedures
  • Diagnosis of an immunodeficiency or immunocompromised state
  • Diagnosis of cystic fibrosis
  • Inability to read and understand English
  • Current participation in another clinical trial at the time of the screening visit
  • Participant is unable to undergo an awake procedure

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Chronic sinusitis is one of the most common chronic diseases in North America, with over 5% of the Canadian population affected by the disease. Until now, treatment with surgery has been performed only in the operating room. Recently a smaller surgical procedure that is done in the clinic for some patients with chronic sinusitis with polyps has been found to result in symptom control that appears to be similar to that which occurs with sinus surgery. Performing the smaller clinical procedure has advantages including a shorter recovery time for the patient, a much lower cost to the health care system for the procedure, and a shorter patient wait time for the procedure to be done in comparison to sinus surgery performed in the operating room. To know with greater certainty that the procedure performed in the clinic is as good as the operating room sinus surgery, a large multiple investigator randomised clinical trial has been designed. However, before carrying out that trial, a practice run or internal pilot study of that trial is required to ensure that the trial can recruit patients at the rate that is anticipated and that the procedures to obtain the measurements being used for the larger study are adequate.

The 2 groups in the trial

  • EPICTreatment being tested

    The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic. The participant will be discharged home from the clinic following their procedure.

    Treatment: Endoscopic Polypectomy Performed in Clinic

  • FESSExisting treatment, for comparison

    The control intervention is functional endoscopic sinus surgery (FESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia

    Treatment: Functional Endoscopic Sinus Surgery (FESS)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Endoscopic Polypectomy Performed In Clinic (EPIC) for Chronic Rhinosinusitis With Polyps: Pilot Study of The EPIC Randomised Controlled Trial
Record updated
30 December 2025